Narlumosbart

纳鲁索拜单抗

Report date: 2024/12/06 11:02:03

Base Information

Drug NameNarlumosbart
Drug Alias NameAnti-RANKL Monoclonal Antibody(Shanghai Jinmante Biotechnology)重组全人源抗RANKL单抗（津曼特生物）纳鲁索拜单抗纳乐舒单抗津立生 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesGlucocorticoid-induced osteoporosisSolid tumours +[10] 
Global Approved IndicationsGiant Cell Tumor of Bone
Approved Indications in ChinaGiant Cell Tumor of Bone
Original Approved Country/TerritoryMainland China
Original Approved Date2023/09/05
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Jmt-Bio Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Jmt-Bio Inc
Inactive CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co Ltd
Active IndicationsBone metastasesSolid tumoursHypercalcemia +[7] 
Inactive IndicationsGlucocorticoid-induced osteoporosisOsteoporosisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A